New clotting Drug's staying power tested in hemophilia a patients
NCT ID NCT05042440
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tested a new drug called efanesoctocog alfa in 13 adults with severe hemophilia A. The goal was to see how long it stays active in the body compared to standard clotting factor treatments. Participants received single injections of each drug in a fixed order, and researchers measured drug levels and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1000001
Sofia, 1756, Bulgaria
Conditions
Explore the condition pages connected to this study.